This combination increased both systemic and intratumoral levels of activated CD8+ T cells, reduced levels of Treg cells, and enhanced infiltration of B cells in the TME, demonstrating the potential of BSA1‐SeNPs for cancer immunotherapy. Here, CD8A is linked to cancer.